A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy

Launched by CHILDREN'S HOSPITAL OF FUDAN UNIVERSITY · Apr 30, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a specific type of epilepsy known as KCNQ2 gene-associated neonatal epileptic encephalopathy, which affects newborns and can cause seizures. The researchers want to understand the causes and factors that influence these seizures, aiming to improve how we identify and manage this condition. They hope to develop better ways to assess and provide care for babies experiencing these kinds of seizures, ultimately helping families understand and cope with the challenges that come with it.

To participate in this study, babies must be less than 28 days old and have experienced their first seizure during the neonatal period. Parents will need to give their consent for their child to take part. The trial is currently recruiting participants and welcomes infants of any gender. By joining the study, families can help contribute to important research that seeks to improve treatment and support for newborns dealing with this serious condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Primary or initial convulsion
• • Postnatal age \<28 days.
• • Seizure in the neonatal period
• • Informed consent of parents
• Exclusion Criteria:
• • Seizure caused by congenital cerebral hypoplasia or multiple structural malformations.
• • Seizure caused by other system-related syndromes.
• • Seizure caused by perinatal or postpartum factors such as HIE, infection, intracranial hemorrhage, etc.